Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089316941> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W3089316941 endingPage "S732" @default.
- W3089316941 startingPage "S732" @default.
- W3089316941 abstract "Dendritic cells (DCs) are highly specialized antigen-presenting cells which are essential for the activation of immune responses. Autologous DCs, directly isolated from peripheral blood, loaded with tumor antigens and matured in vitro, can induce tumor-specific immune responses and clinical responses in cancer patients. In this phase III clinical trial, patients with resected stage IIIB or IIIC cutaneous melanoma (AJCC 7th edition) were randomized in a 2:1 ratio to adjuvant treatment with DC vaccination or placebo. The active treatment arm consisted of intranodal injections with autologous CD1c+ myeloid DCs and plasmacytoid DCs loaded with tumor antigens (gp100, tyrosinase, MAGE-C2, MAGE-A3 and NY-ESO-1). When adjuvant treatment with anti-PD1 antibodies became available in the Netherlands in November 2018, accrual was stopped prematurely after inclusion of 151 patients. The primary endpoint is the 2-year recurrence-free survival (RFS) rate. Secondary endpoints include overall survival, immunological response and safety. In January 2020, we performed a preplanned interim analysis. At that time, 102 patients reached mature data for primary endpoint analysis (recurrence of disease within 2 years of randomisation or at least 2-year follow-up). Thirty-eight percent of patients were female and the median age at start was 55.7 years (range 27-78). At inclusion, 51% of patients had stage IIIB disease and 49% stage IIIC disease. Two-year RFS rate was 21.4% in the treatment arm and 25% in the control arm (HR 1.05; 95% CI: 0.47-3.23), providing no statistically significant evidence of a treatment effect (p=0.67). Our phase III clinical trial with adjuvant DC vaccination in stage IIIB and IIIC melanoma patients showed no benefit over placebo in terms of 2-year RFS. Correlative analysis of skin-test infiltrating lymphocytes for markers of immunological and clinical response are ongoing." @default.
- W3089316941 created "2020-10-01" @default.
- W3089316941 creator A5002745380 @default.
- W3089316941 creator A5009376752 @default.
- W3089316941 creator A5019285650 @default.
- W3089316941 creator A5020846362 @default.
- W3089316941 creator A5021244456 @default.
- W3089316941 creator A5024976681 @default.
- W3089316941 creator A5039709555 @default.
- W3089316941 creator A5043211028 @default.
- W3089316941 creator A5049357980 @default.
- W3089316941 creator A5051830427 @default.
- W3089316941 creator A5056129636 @default.
- W3089316941 creator A5064760248 @default.
- W3089316941 creator A5086571483 @default.
- W3089316941 date "2020-09-01" @default.
- W3089316941 modified "2023-09-30" @default.
- W3089316941 title "1078MO MIND-DC: A randomized phase III trial to assess the efficacy of adjuvant dendritic cell vaccination in comparison to placebo in stage IIIB and IIIC melanoma patients" @default.
- W3089316941 doi "https://doi.org/10.1016/j.annonc.2020.08.1202" @default.
- W3089316941 hasPublicationYear "2020" @default.
- W3089316941 type Work @default.
- W3089316941 sameAs 3089316941 @default.
- W3089316941 citedByCount "5" @default.
- W3089316941 countsByYear W30893169412021 @default.
- W3089316941 countsByYear W30893169412023 @default.
- W3089316941 crossrefType "journal-article" @default.
- W3089316941 hasAuthorship W3089316941A5002745380 @default.
- W3089316941 hasAuthorship W3089316941A5009376752 @default.
- W3089316941 hasAuthorship W3089316941A5019285650 @default.
- W3089316941 hasAuthorship W3089316941A5020846362 @default.
- W3089316941 hasAuthorship W3089316941A5021244456 @default.
- W3089316941 hasAuthorship W3089316941A5024976681 @default.
- W3089316941 hasAuthorship W3089316941A5039709555 @default.
- W3089316941 hasAuthorship W3089316941A5043211028 @default.
- W3089316941 hasAuthorship W3089316941A5049357980 @default.
- W3089316941 hasAuthorship W3089316941A5051830427 @default.
- W3089316941 hasAuthorship W3089316941A5056129636 @default.
- W3089316941 hasAuthorship W3089316941A5064760248 @default.
- W3089316941 hasAuthorship W3089316941A5086571483 @default.
- W3089316941 hasConcept C126322002 @default.
- W3089316941 hasConcept C141071460 @default.
- W3089316941 hasConcept C143998085 @default.
- W3089316941 hasConcept C147483822 @default.
- W3089316941 hasConcept C203014093 @default.
- W3089316941 hasConcept C203092338 @default.
- W3089316941 hasConcept C2776090121 @default.
- W3089316941 hasConcept C2777658100 @default.
- W3089316941 hasConcept C2777863537 @default.
- W3089316941 hasConcept C2779053233 @default.
- W3089316941 hasConcept C502942594 @default.
- W3089316941 hasConcept C535046627 @default.
- W3089316941 hasConcept C61943457 @default.
- W3089316941 hasConcept C71924100 @default.
- W3089316941 hasConcept C8891405 @default.
- W3089316941 hasConcept C90924648 @default.
- W3089316941 hasConceptScore W3089316941C126322002 @default.
- W3089316941 hasConceptScore W3089316941C141071460 @default.
- W3089316941 hasConceptScore W3089316941C143998085 @default.
- W3089316941 hasConceptScore W3089316941C147483822 @default.
- W3089316941 hasConceptScore W3089316941C203014093 @default.
- W3089316941 hasConceptScore W3089316941C203092338 @default.
- W3089316941 hasConceptScore W3089316941C2776090121 @default.
- W3089316941 hasConceptScore W3089316941C2777658100 @default.
- W3089316941 hasConceptScore W3089316941C2777863537 @default.
- W3089316941 hasConceptScore W3089316941C2779053233 @default.
- W3089316941 hasConceptScore W3089316941C502942594 @default.
- W3089316941 hasConceptScore W3089316941C535046627 @default.
- W3089316941 hasConceptScore W3089316941C61943457 @default.
- W3089316941 hasConceptScore W3089316941C71924100 @default.
- W3089316941 hasConceptScore W3089316941C8891405 @default.
- W3089316941 hasConceptScore W3089316941C90924648 @default.
- W3089316941 hasLocation W30893169411 @default.
- W3089316941 hasOpenAccess W3089316941 @default.
- W3089316941 hasPrimaryLocation W30893169411 @default.
- W3089316941 hasRelatedWork W1993025569 @default.
- W3089316941 hasRelatedWork W2043775195 @default.
- W3089316941 hasRelatedWork W2087047282 @default.
- W3089316941 hasRelatedWork W2093242067 @default.
- W3089316941 hasRelatedWork W2095304551 @default.
- W3089316941 hasRelatedWork W2166919567 @default.
- W3089316941 hasRelatedWork W2220102944 @default.
- W3089316941 hasRelatedWork W2478440915 @default.
- W3089316941 hasRelatedWork W3109192410 @default.
- W3089316941 hasRelatedWork W276659083 @default.
- W3089316941 hasVolume "31" @default.
- W3089316941 isParatext "false" @default.
- W3089316941 isRetracted "false" @default.
- W3089316941 magId "3089316941" @default.
- W3089316941 workType "article" @default.